238 related articles for article (PubMed ID: 30218317)
1. Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):421-428. PubMed ID: 30218317
[TBL] [Abstract][Full Text] [Related]
2. Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction.
Lasnon C; Salomon T; Desmonts C; Dô P; Oulkhouir Y; Madelaine J; Aide N
Ann Nucl Med; 2017 Feb; 31(2):125-134. PubMed ID: 27812791
[TBL] [Abstract][Full Text] [Related]
3.
Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
[TBL] [Abstract][Full Text] [Related]
4. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients.
Lasnon C; Desmonts C; Quak E; Gervais R; Do P; Dubos-Arvis C; Aide N
Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):985-96. PubMed ID: 23564036
[TBL] [Abstract][Full Text] [Related]
5. Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients.
Quak E; Le Roux PY; Hofman MS; Robin P; Bourhis D; Callahan J; Binns D; Desmonts C; Salaun PY; Hicks RJ; Aide N
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2072-82. PubMed ID: 26219870
[TBL] [Abstract][Full Text] [Related]
6. Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer.
Houdu B; Lasnon C; Licaj I; Thomas G; Do P; Guizard AV; Desmonts C; Aide N
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):533-534. PubMed ID: 30535744
[TBL] [Abstract][Full Text] [Related]
7. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
[TBL] [Abstract][Full Text] [Related]
8. SUV Harmonization Between Different Hybrid PET/CT Systems.
Rubello D; Colletti PM
Clin Nucl Med; 2018 Nov; 43(11):811-814. PubMed ID: 30199381
[TBL] [Abstract][Full Text] [Related]
9. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
11. Variability and Repeatability of Quantitative Uptake Metrics in
Zhuang M; García DV; Kramer GM; Frings V; Smit EF; Dierckx R; Hoekstra OS; Boellaard R
J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
[TBL] [Abstract][Full Text] [Related]
12. Impact of the EARL harmonization program on automatic delineation of metabolic active tumour volumes (MATVs).
Lasnon C; Enilorac B; Popotte H; Aide N
EJNMMI Res; 2017 Dec; 7(1):30. PubMed ID: 28361349
[TBL] [Abstract][Full Text] [Related]
13. EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems.
Kaalep A; Sera T; Oyen W; Krause BJ; Chiti A; Liu Y; Boellaard R
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):412-422. PubMed ID: 29192365
[TBL] [Abstract][Full Text] [Related]
14. Does PET Reconstruction Method Affect Deauville Score in Lymphoma Patients?
Enilorac B; Lasnon C; Nganoa C; Fruchart C; Gac AC; Damaj G; Aide N
J Nucl Med; 2018 Jul; 59(7):1049-1055. PubMed ID: 29242403
[TBL] [Abstract][Full Text] [Related]
15. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of state of the art PET/CT systems performance harmonisation.
Kaalep A; Sera T; Rijnsdorp S; Yaqub M; Talsma A; Lodge MA; Boellaard R
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1344-1361. PubMed ID: 29500480
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the Role of PET/CT SUVmax in Prognosis and Its Correlation with
Clinicopathological Characteristics in Resectable Lung Squamous Cell Carcinoma].
Ren H; Xu W; You J; Song X; Huang H; Zhao N; Ren X; Zhang X
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):192-9. PubMed ID: 27118646
[TBL] [Abstract][Full Text] [Related]
18. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
[TBL] [Abstract][Full Text] [Related]
19. How Often Do We Fail to Classify the Treatment Response with [
Mattoli MV; Calcagni ML; Taralli S; Indovina L; Spottiswoode BS; Giordano A
Mol Imaging Biol; 2019 Dec; 21(6):1210-1219. PubMed ID: 30850971
[TBL] [Abstract][Full Text] [Related]
20. EARL compliance and imaging optimisation on the Biograph Vision Quadra PET/CT using phantom and clinical data.
van Sluis J; van Snick JH; Brouwers AH; Noordzij W; Dierckx RAJO; Borra RJH; Slart RHJA; Lammertsma AA; Glaudemans AWJM; Boellaard R; Tsoumpas C
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4652-4660. PubMed ID: 35876867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
